Transgenomic, Amgen announce cancer collaboration
OMAHA, Neb.—Biotechnology company Transgenomic Inc. and Amgen Inc. have begun a collaboration for the development of a CE-IVD test to screen patients with metastatic colorectal cancer for RAS mutations. The RAS mutations—KRAS and NRAS—identified via the CE-IVD CRC RAScan kits provide physicians with information on tumor mutation status. No financial terms for the agreement were released.
"This collaboration with Amgen is indicative of how Transgenomic's proprietary molecular technologies are advancing personalized medicine," Craig Tuttle, CEO of Transgenomic, commented in a press release about the collaboration. "This highly precise, innovative test was developed at Transgenomic's laboratories, which excel in genomic and genetic analysis, novel technology development and its application in clinical research and trials."